Lung cancer is the second most common cancer in both men and women. Of all the lung cancer cases reported, 85% are non-small cell lung cancer (NSCLC). Although current treatments have improved the overall survival rate, success is limited, with serious treatment-related adverse effects reported. In addition, an increase in drug-resistant cancer cells limits the available treatment options. Antimicrobial peptides (AMPs) have gained much interest as anticancer drugs as they can selectively kill cancer cells but not healthy cells. Further, AMPs show minimal toxicity and minimal chances for developing resistance. In this review, I discuss the advantages of AMPs, their mechanism of action, and progress in AMP development for use in NSCLC treatment.

中文翻译：

---

抗菌肽作为非小细胞肺癌的新型疗法。

肺癌是男性和女性中第二大最常见的癌症。在报告的所有肺癌病例中，有85％是非小细胞肺癌（NSCLC）。尽管目前的治疗提高了总生存率，但成功有限，报道了与治疗相关的严重不良反应。另外，耐药性癌细胞的增加限制了可用的治疗选择。抗菌肽（AMPs）作为抗癌药物引起了广泛兴趣，因为它们可以选择性杀死癌细胞，但不能杀死健康细胞。另外，AMP显示出最小的毒性和最小的产生抗药性的机会。在这篇综述中，我将讨论AMP的优势，它们的作用机制以及用于NSCLC治疗的AMP开发进展。